Abeona therapeutics announces acceptance of abstract on eb-101 phase 3 viital™ study results for oral presentation at international societies for investigative dermatology (isid) 2023 meeting

New york and cleveland, march 16, 2023 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo) today announced that additional data from its pivotal phase 3 viital™ study of eb-101 for recessive dystrophic epidermolysis bullosa (rdeb) has been accepted for an oral presentation at the inaugural international societies for investigative dermatology (isid) meeting, being held may 10-13, 2023 in tokyo, japan. abeona previously reported positive top-line efficacy and safety data from the viital study in november 2022.
ABEO Ratings Summary
ABEO Quant Ranking